Status:
TERMINATED
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Lead Sponsor:
Tocagen Inc.
Conditions:
Glioblastoma Multiforme
Astrocytoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations. Subjects wil...
Eligibility Criteria
Inclusion
- Informed Consent Form
- Subject received Toca 511 in prior study.
- Subject is willing to abide by protocol
Exclusion
- Subject has history of allergy or intolerance to flucytosine
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04327011
Start Date
February 1 2011
End Date
December 1 2019
Last Update
March 30 2020
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
2
UCSD
San Diego, California, United States, 92093
3
UCSF
San Francisco, California, United States, 94143
4
Henry Ford Health System
Detroit, Michigan, United States, 48202